Clinical Trials Logo
  1. Home
  2. Recurrent Ovarian Cancer
  3. NCT03618706

Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Recurrent Ovarian Cancer Clinical Trial

Official title:
A Phase II Trial of Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Clinical Trial Summary

This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field RT improves 2-year PFS in those patients than that of historical data (only with other standard salvage treatments as systemic chemotherapy ± maximum tumor resection).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03618706
Study type Interventional
Source Yonsei University
Contact Yong Bae Kim, MD, PhD
Phone 82-2228-8095
Email ybkim3@yuhs.ac
Status Recruiting
Phase Phase 2
Start date May 10, 2018
Completion date May 9, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02195973 - Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Phase 1
Not yet recruiting NCT05270720 - Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer Phase 1
Not yet recruiting NCT06070285 - Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Completed NCT02303912 - Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT01802749 - Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Phase 3
Completed NCT02788708 - Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Phase 1
Recruiting NCT03564340 - Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Phase 1/Phase 2
Recruiting NCT05610735 - Combination Therapy for Recurrent Ovarian Cancer Phase 1/Phase 2
Withdrawn NCT02083536 - LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Phase 1
Completed NCT03430518 - Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Phase 1
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT01851746 - A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer N/A
Active, not recruiting NCT06107868 - Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer Phase 1
Recruiting NCT06308406 - A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06365853 - A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Phase 2
Completed NCT04718740 - A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT05335993 - A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Phase 2
Completed NCT01381861 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Phase 2
Not yet recruiting NCT05126342 - Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi Phase 2
Completed NCT02849353 - Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer Phase 1/Phase 2